VYTRUS BIOTECH EO -01
Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. The company offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Ca… Read more
Market Cap & Net Worth: VYTRUS BIOTECH EO -01 (V5P)
VYTRUS BIOTECH EO -01 (F:V5P) has a market capitalization of $80.97 Million (€78.88 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #21938 globally and #2386 in its home market, demonstrating a 10.78% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying VYTRUS BIOTECH EO -01's stock price €11.30 by its total outstanding shares 6980516 (6.98 Million).
VYTRUS BIOTECH EO -01 Market Cap History: 2022 to 2026
VYTRUS BIOTECH EO -01's market capitalization history from 2022 to 2026. Data shows growth from $24.00 Million to $80.97 Million (33.87% CAGR).
VYTRUS BIOTECH EO -01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how VYTRUS BIOTECH EO -01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of V5P by Market Capitalization
Companies near VYTRUS BIOTECH EO -01 in the global market cap rankings as of March 19, 2026.
Key companies related to VYTRUS BIOTECH EO -01 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
VYTRUS BIOTECH EO -01 Historical Marketcap From 2022 to 2026
Between 2022 and today, VYTRUS BIOTECH EO -01's market cap moved from $24.00 Million to $ 80.97 Million, with a yearly change of 33.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €80.97 Million | +7.62% |
| 2025 | €75.24 Million | +386.11% |
| 2024 | €15.48 Million | -22.86% |
| 2023 | €20.06 Million | -16.42% |
| 2022 | €24.00 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of VYTRUS BIOTECH EO -01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $80.97 Million USD |
| MoneyControl | $80.97 Million USD |
| MarketWatch | $80.97 Million USD |
| marketcap.company | $80.97 Million USD |
| Reuters | $80.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.